Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal — Hagens Berman
Simulations Plus's revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether the company may have misled investors about its asset valuations and the reasons why it abruptly dismissed Grant Thornton and urges Simulations Plus investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.
Visit: www.hbsslaw.com/investor-fraud/slp
Contact the Firm Now: [email protected]
844-916-0895
Simulations Plus, Inc. (SLP) Investigation:
The investigation is focused on the propriety of Simulations Plus' statements concerning its asset values and the basis of its dismissal of independent auditor Grant Thornton.
The inquiry stems from a series of events earlier this month. On July 14, Simulations Plus announced a $77.2 million charge, stating it adjusted the book value of its assets to align with current market values. The following day, in a separate disclosure, the company revealed it had terminated its engagement with Grant Thornton on July 9. Simulations Plus had initially hired Grant Thornton on April 15, 2025.
Simulations Plus explained the auditor change by stating that during Grant Thornton's brief tenure, the company reviewed matters concerning segment reporting and reporting unit determinations that could not be finalized for its May 31, 2025, quarterly report. The company also evaluated internal controls over financial reporting related to Sarbanes-Oxley Act Section 404(a) compliance, concluding these could not be finalized in time for the same report. Simulations Plus added that there were no 'reportable events' as defined by SEC regulations.
Grant Thornton, however, disputed Simulations Plus's account in a letter to the Securities and Exchange Commission. The auditing firm stated its disagreement with the company's disclosure. Grant Thornton further indicated that during its review of Simulations Plus's consolidated financial statements for the quarter ended May 31, 2025, it had identified and communicated specific concerns to management and the Audit Committee related to segment reporting, reporting unit determinations, and internal controls over financial reporting.
'We're investigating whether Simulations Plus may have misled investors about the value of its assets and why it abruptly fired Grant Thornton and rehired its old auditor,' said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in Simulations Plus and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »
If you'd like more information and answers to frequently asked questions about the Simulations Plus investigation, read more »
Whistleblowers: Persons with non-public information regarding Simulations Plus should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Should You Forget Costco? Why These Unstoppable Stocks Are Better Buys
Key Points Costco is a retail powerhouse, using a membership model to create an annuity-like income stream. Investors know exactly how well the business is performing right now. If you care about valuation, you'll probably be better off with these out-of-favor dividend machines. 10 stocks we like better than Costco Wholesale › Costco (NASDAQ: COST) has increased its dividend annually for over two decades. That's an impressive dividend streak, but the story today is all about growth. While Costco is doing well on the growth front, investors are also well aware of that fact. That's why a couple of reliable dividend-paying consumer staples alternatives might be better options. The problem with Costco Costco operates club stores, which is somewhat unusual in the broader retail sector. Essentially, its customers pay a membership fee to shop at a Costco. That creates a reliable and recurring source of revenues that allows Costco to operate with tighter profit margins. It's a virtuous circle, since lower prices keep customers happily coming back (and paying their membership fees). The best example of the strength of the model is the roughly 90% member renewal rate. Right now, Costco is performing very well as a business, with new store openings. Customers are returning more often, and spending more every time they visit. The problem with Costco isn't the business -- it's the stock. Right now, the price-to-sales (P/S), price-to-earnings (P/E), and price-to-book value (P/B) ratios are all well above their five-year averages. The dividend yield is a miserly 0.6% or so. Investors are pricing a lot of good news into Costco's stock. If you care about valuation, consider Coca-Cola and PepsiCo Investors who are focused on income will clearly not be happy with Costco's tiny dividend yield. Investors who care at all about valuation will also be disappointed with the stock. There are better options on both fronts, with Dividend Kings Coca-Cola (NYSE: KO) and PepsiCo (NASDAQ: PEP) ranking high on the income and value fronts. Coca-Cola will likely be the easier sell here. This beverage giant is performing quite well right now relative to PepsiCo. In the second quarter, Coca-Cola was able to grow organic revenues by a solid 5%, despite people's reluctance to spend their money thanks to inflationary concerns. Essentially, Coca-Cola sells an affordable luxury that people appear willing to buy no matter what. This strongly performing Dividend King, with over six decades of dividend increases behind it, isn't exactly cheap. But, unlike Costco, the stock appears reasonably priced. The P/S, P/E, and P/B ratios are all roughly at or slightly below their five-year averages. And while the stock's dividend yield is on the low side, historically speaking, it is still fairly attractive on an absolute basis at 3%. If you want to buy a good company that's performing well, Coca-Cola is a better value than Costco right now. PepsiCo will appeal to investors with a deeper value bias, given that its P/S, P/E, and P/B ratios are soundly below their five-year averages. The dividend yield, at roughly 4%, is high on both a historical basis and on an absolute basis. That said, PepsiCo isn't performing nearly as well as Coca-Cola at the moment. For example, PepsiCo's organic sales rose just 2.1% in the second quarter. That's less than half as much as Coca-Cola's organic sales growth in the same period. Clearly, investors recognize the underperformance and have priced PepsiCo's stock accordingly. But if you are a dividend investor or a value investor, this is likely to be an opportunity. PepsiCo is a Dividend King with over five decades of annual dividend increases behind it. It has muddled through bad times before. Moreover, it's a more diversified business, operating in the beverage, salty snack, and packaged food niches of the food sector. So there are more levers to pull on the growth front as the company looks to get back on track. Notably, it recently bought a probiotic beverage maker to augment its beverage business, and a Mexican-American food producer to supplement its food operations. In time, it's likely that PepsiCo will get back on track, and you'll get to collect a lofty yield while you wait. Costco is too expensive -- Coca-Cola and PepsiCo are better choices There's nothing wrong with Costco's business. The valuation of the stock is the problem. If you don't want to overpay for a company, you'll be better off with Coca-Cola or PepsiCo. Coca-Cola offers a strongly performing business and a reasonably priced stock. PepsiCo offers a relatively cheap stock backed by a historically well-run business going through tough times. Both Coca-Cola and PepsiCo have long provided unstoppable dividend growth. Should you buy stock in Costco Wholesale right now? Before you buy stock in Costco Wholesale, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Costco Wholesale wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Reuben Gregg Brewer has positions in PepsiCo. The Motley Fool has positions in and recommends Costco Wholesale. The Motley Fool has a disclosure policy. Should You Forget Costco? Why These Unstoppable Stocks Are Better Buys was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Why Is Electronic Arts (EA) Stock Rocketing Higher Today
What Happened? Shares of video game publisher Electronic Arts (NASDAQ:EA) jumped 5.8% in the morning session after the company reported strong first-quarter financial results that surpassed expectations, overshadowing a weaker outlook for the upcoming quarter. The video game publisher announced strong preliminary financial results for its first quarter, reporting net revenue of $1.671 billion and net bookings of $1.298 billion, both of which surpassed expectations. Despite the strong performance, the company also issued a weaker-than-expected forecast for its second quarter, which initially caused the stock to dip in after-hours trading. The company attributed the softer outlook to the timing of revenue recognition for upcoming game releases and increased marketing expenses. However, investor sentiment appeared to shift, focusing on the current strong results over the future guidance. The positive move was also supported by B of A Securities, which raised its price target on the stock to $168 from $166. Is now the time to buy Electronic Arts? Access our full analysis report here, it's free. What Is The Market Telling Us Electronic Arts's shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 8 days ago when the stock gained 3.2% on the news that the company received a vote of confidence from Wall Street. Analyst Alicia Reese at Wedbush reaffirmed an "Outperform" rating on the stock. An "Outperform" rating suggests the analyst believes the stock will achieve returns superior to the broader market average. Electronic Arts is up 8.5% since the beginning of the year, and at $158.32 per share, it is trading close to its 52-week high of $167.97 from November 2024. Investors who bought $1,000 worth of Electronic Arts's shares 5 years ago would now be looking at an investment worth $1,142. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
